Capricor Therapeutics, Inc. (CAPR) News
Filter CAPR News Items
CAPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CAPR News Highlights
- CAPR's 30 day story count now stands at 2.
- Over the past 2 days, the trend for CAPR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC are the most mentioned tickers in articles about CAPR.
Latest CAPR News From Around the Web
Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.
Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five yearsOver the last month the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) has been much stronger than before, rebounding by... |
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- --Company Plans to Request a Meeting with FDA in the First Quarter of 2024 to Further Discuss Opportunities for Expedited Approval Pathways-- SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), |
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call TranscriptCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded. I would now like to turn the conference call over to our host, Mr. AJ Bergmann, Capricor’s […] |
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with Nippon Shinyaku- -Positive FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application Submission- -Conference Call and Webcast Today |
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14Company to Host Conference Call, November 14, 2023, at 4:30 p.m. ETSAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023. Management will then host a webcast |
Smart for Life, Inc. (SMFL) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseSmart for Life, Inc. (SMFL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to DeclineCapricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |